Literature DB >> 9327347

Mitomycin C primary trabeculectomy in primary glaucoma of white patients.

R M Nuijts1, R C Vernimmen, C A Webers.   

Abstract

PURPOSE: To evaluate the clinical outcome of eyes which underwent primary trabeculectomy with adjunctive mitomycin C (MMC) for primary glaucoma. PATIENTS AND METHODS: A prospective analysis of 25 eyes in 23 patients who underwent primary trabeculectomy with MMC for primary glaucoma was performed. Clinical outcome measures including postoperative intraocular pressure, change in logarithm of the minimum angle of resolution (LogMAR) visual acuity, and incidence of complications were measured up to 1 year postoperatively.
RESULTS: Mean intraocular pressure decreased from 26.0 +/- 4.4 mmHg preoperatively to 12.5 +/- 3.9 mmHg (p < 0.0001) 1 year postoperatively. The mean LogMAR visual acuity changed from 0.23 +/- 0.19 preoperatively to 0.23 +/- 0.20 1 year postoperatively (p = 1.0). One eye developed a temporary hypotonous maculopathy and 4 eyes progressed in cataract formation.
CONCLUSION: Primary trabeculectomy with MMC in eyes with primary glaucoma showed excellent pressure reduction. There were no cases of persistent hypotonous maculopathy or bleb endophthalmitis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9327347

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  3 in total

1.  Does titration of mitomycin C as an adjunct to trabeculectomy significantly influence the intraocular pressure outcome?

Authors:  Susan J Lee; Augusto Paranhos; M Bruce Shields
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 2.  Mitomycin: clinical applications in ophthalmic practice.

Authors:  Lekha M Abraham; Dinesh Selva; Robert Casson; Igal Leibovitch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

3.  Ocular surface disease in posttrabeculectomy/mitomycin C patients.

Authors:  Janice Lam; Tina T Wong; Louis Tong
Journal:  Clin Ophthalmol       Date:  2015-01-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.